RGTA® technology’s breakthrough potential is supported
by more than 100 preclinical and clinical publications

liseret1
liseret2

Main publications and articles on RGTA® :

All
Graft
Neurology
Musculoskeletal and Locomotor
Imaging
Cardiovascular
Gastro-Intestinal
Dermatology
Ophtalmology
Other
Oncology
Stem Cells
Dental and Oral
Urology and Gynecology
RGTA technology
CACICOL
Cacipliq 20

A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis

Effect of a Matrix Therapy Agent on Corneal Epithelial Healing After Standard Collagen Cross-linking in Patients With Keratoconus: A Randomized Clinical Trial

A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle

A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers

A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke

Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta1.

Diabetes-Impaired Wound Healing Is Improved by Matrix Therapy With Heparan Sulfate Glycosaminoglycan Mimetic OTR4120 in Rats.

RGTA(R) or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

liseret1
liseret2
Publications
Publications

Organes Tissus Regeneration Reparation Remplacement

© 2022 – OTR3 – All rights reserved

ADDRESS

4, rue Française
75001 Paris, France

© 2022 – OTR3 – All rights reserved